Skip to main content
Equibles
OBIO logo

OBIO · Orchestra BioMed Holdings, Inc.

Track OBIO — free

Use OBIO with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$4.94 +0.04 (+0.82%)
Russell 2000 member Rebalance outlook locked
Market Cap
$294.51M
Shares
60.11M

OBIO metrics

65 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.90
Market cap
$294.51M

Price action

19 metrics
Price change (1W)
-8.6%
Price change (30D)
+18.9%
Price change (3M)
+25.3%
Price change (6M)
+12.4%
Price change (YTD)
+18.1%
Price change (1Y)
+79.5%
Trailing year
Price change (5Y)
-50.0%
52-week high
$5.66
52-week low
$2.35
Change from 52-week high
-13.4%
Change from 52-week low
+108.5%
Annualized volatility
67.9%
Beta
1.5
RSI (14D)
53.8
Price vs SMA 50
+13.3%
Price vs SMA 200
+14.9%
Avg volume (3M)
341,419
Relative volume
0.6
Average dollar volume
$1.50M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
60.11M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
9.2×
reciprocal yield 10.9%
P / book
15.2
reciprocal yield 6.6%
FCF yield
-20.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-20.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
29.9×
reciprocal yield 3.3%
EV / revenue historical average (5Y)
29.9×
reciprocal yield 3.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
99.5%
Operating margin
-181.4%
Trailing 12 months
Net margin
-184.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$57.99M
Net income (TTM)
−$59.03M
Trailing 12 months
Diluted EPS (TTM)
$-0.83
FCF margin
-184.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
-89.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$31.98M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+66.2%
Year over year · more shares
Revenue CAGR (3Y)
+111.6%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-305.5%
Return on assets
-51.0%
Debt / equity
—
Current ratio
8.3
EBITDA (TTM)
−$57.64M
Free cash flow (TTM)
−$59.10M
Quick ratio
8.2
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$20.47M
Total assets
$115.70M
Total debt
$15.00M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$58.32M
Capital expenditures (TTM)
$781,000
R&D (TTM)
$63.22M
SG&A (TTM)
$26.59M
Stock compensation (TTM)
$11.12M
R&D / revenue
197.7%
Stock compensation / revenue
34.8%

Ownership (13F)

3 metrics
13F filers
77
13F filer change QoQ
+12
Institutional ownership
46.1%

Short interest

3 metrics
Short interest
4.0%
Latest settlement · 13.1 days to cover
Days to cover
13.1d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$114,740
Insider-sentiment score
74 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1814114 CUSIP 68572M106 13F (30d) 64 filings 64 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)